Antimicrobial-resistant infections affect more than 2 million people annually in the United States alone, accounting for an estimated 23 000 deaths and estimated economic costs of $55 billion.1 Recent projections suggest that an estimated 300 million people worldwide could die prematurely in the next 35 years because of antimicrobial-resistant infections.2 Physicians are more frequently prescribing antibiotics of last resort (such as colistin and carbapenem), raising concerns that once-curable infections will have no viable treatments.3
Daniel GW, Schneider M, McClellan MB. Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award. JAMA. 2017;318(12):1103–1104. doi:10.1001/jama.2017.10164
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.